摘要
目的:评价乳腺康口服液和注射液在家兔体内生物等效性。方法:采用紫外分光光度法测定血药浓度。结果:乳腺康口服液和注射液的Tmax分别为(3.8065±1.009)h和(1.0809±0.59)h,Cmax为(0.5333±0.03)和(0.5328±0.16)mg/ml,AUC为(3.1095±0.9)和(2.8938±0.14)mg/ml,t1/2为(3.1035±1.0143)和(2.8720±0.93)h,乳腺康口服液相对生物利用度为106.1%。结论:经统计学分析,乳腺康口服液和注射液具有生物等效性。
Objective: to observe the bioavailability of Ruxiankang oral liquid and injection. Methods: The plasma concentration of Ruxiankang oral liquid, was determined by UV-spectrophotometric methods. Results: The main pharmacokinetics of the two produts were as follow: T max, (3.8065±1.009)h and(1.0809±0.59)h; Cmax, (0.5333±0.03)mg/ml and(0.5328±0.16) mg/ml; AUC, (3.1095±0.9) mg/ml and(2.8938±0.14)mg/ml, and t , (3.1035±1.0143)h and (2.8720±0.93)h, respectively. The relative bioavailability of Ruxiankang oral liquid was 106.1%。Conclusion: There were no significant difference between the two parameters (P>0.05), demonstrating that the two preparations have the same bioquivalence.
出处
《黑龙江医药科学》
2002年第5期49-50,共2页
Heilongjiang Medicine and Pharmacy
